Skip to main content Back to Top
Advertisement

8/29/2024

Haloperidol Lactate Injection

Products Affected - Description

    • Haloperidol lactate solution for injection, Hikma, 5 mg/mL, 1 mL vial, 25 count, NDC 00143-9501-25
    • Haloperidol lactate solution for injection, Hikma, 5 mg/mL, 10 mL vial, 1 count, NDC 00143-9502-01

Reason for the Shortage

    • Fresenius Kabi has haloperidol lactate injection available.
    • Hikma did not provide a reason for the shortage.
    • Sagent has haloperidol lactate injection available.
    • Viatris has haloperidol lactate injection available.

Available Products

    • Haloperidol lactate injection, Fresenius Kabi, 5 mg/mL, 1 mL Simplist prefilled syringe, 24 count, NDC 76045-0737-10
    • Haloperidol lactate solution for injection, Fresenius Kabi, 5 mg/mL, 1 mL vial, 25 count, NDC 63323-0474-01
    • Haloperidol lactate solution for injection, Fresenius Kabi, 5 mg/mL, 10 mL vial, 1 count, NDC 63323-0474-10
    • Haloperidol lactate solution for injection, Mylan Institutional (Viatris), 5 mg/mL, 1 mL vial, 25 count, NDC 67457-0426-12
    • Haloperidol lactate solution for injection, Sagent, 5 mg/mL, 1 mL vial, 10 count, NDC 25021-0806-01

Estimated Resupply Dates

    • Hikma has haloperidol lactate injection 5 mg/mL 1 mL and 10 mL vials on back order and the company cannot estimate a release date.

Updated

Updated August 29, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 9, 2020 by Stephen Andrews, PharmD, BCPS, CPPS, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT